home > news

> News

> Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier

News

09/05/2025

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier

Read the full article below.

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier

Our news

News

21/03/2025
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
> READ

News

21/02/2025
Interview of Hervé Affagard, President of EMIH
> READ

News

23/01/2024
Focus SoHO et Paquet Pharma
> READ

> See all news